Pentoxifylline Neuroprotective Effects Are Possibly Related to Its Anti-Inflammatory and TNF-Alpha Inhibitory Properties, in the 6-OHDA Model of Parkinson’s Disease

Figure 7

Representative photomicrographs showing that pentoxifylline treatments (PTX, 15 days) reverse the increased immunoreactivity for the dopamine transporter (DAT) in the 6-OHDA group, relatively to the striatum from the untreated 6-OHDA group. Groups: SO (sham-operated, control), untreated 6-OHDA, and 6-OHDA treated with PTX at the doses of 25 and 50 mg/kg. Ipsilateral = lesioned side, as compared to the unlesioned contralateral side. Magnification: 400x. A versus SO, q = 23.97 ; B versus 6-OHDA + PTX25, q = 20.54 ; C versus 6-OHDA + PTX50, q = 26.36 ; D versus SO, q = 3.247 ; E versus 6-OHDA + PTX25, q = 4.323 (one-way ANOVA and Newman-Keuls as the post hoc test).

(a)

(b)